Gelbard M - Search Results

1

Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.

Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Gelbard M, et al. J Urol. 2012 Jun;187(6):2268-74. doi: 10.1016/j.juro.2012.01.032. Epub 2012 Apr 13. J Urol. 2012. PMID: 22503048 Clinical Trial.

2

Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.

Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd. Gelbard M, et al. J Urol. 2013 Jul;190(1):199-207. doi: 10.1016/j.juro.2013.01.087. Epub 2013 Jan 31. J Urol. 2013. PMID: 23376148 Review.

3

Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.

Gelbard M, Hellstrom WJ, McMahon CG, Levine LA, Smith T, Tursi J, Kaufman G, Goldstein I. Gelbard M, et al. J Sex Med. 2013 Nov;10(11):2822-31. doi: 10.1111/jsm.12312. Epub 2013 Sep 24. J Sex Med. 2013. PMID: 24112401 Clinical Trial.

4

Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.

Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ. Levine LA, et al. J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12. J Sex Med. 2015. PMID: 25388099 Clinical Trial.

5

Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach.

Gelbard MK, Chagan L, Tursi JP. Gelbard MK, et al. J Sex Med. 2015 Jun;12(6):1481-9. doi: 10.1111/jsm.12904. Epub 2015 May 5. J Sex Med. 2015. PMID: 25940867 Review.

6

Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease.

Goldstein I, Lipshultz LI, McLane M, Hu Y, Xiang Q, Liu G, Vijayan S, Gelbard MK. Goldstein I, et al. Among authors: gelbard mk. J Urol. 2020 Jun;203(6):1191-1197. doi: 10.1097/JU.0000000000000743. Epub 2020 Jan 10. J Urol. 2020. PMID: 31922462 Clinical Trial.

7

Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.

Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A, Ziegelmann M, Trost L, Gelbard M. Hellstrom WJG, et al. Among authors: gelbard m. J Urol. 2019 Apr;201(4):777-782. doi: 10.1097/JU.0000000000000032. J Urol. 2019. PMID: 30672843

8

Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional Analysis.

Nguyen HMT, Yousif A, Chung A, Virasoro R, Tapscott A, Ziegelmann M, Trost L, Gelbard M, Hellstrom WJG. Nguyen HMT, et al. Among authors: gelbard m. Urology. 2020 Nov;145:147-151. doi: 10.1016/j.urology.2020.07.048. Epub 2020 Aug 7. Urology. 2020. PMID: 32777367

9

The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman.

Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA. Glina S, et al. J Sex Med. 2007 Sep;4(5):1209-13. doi: 10.1111/j.1743-6109.2007.00581.x. J Sex Med. 2007. PMID: 17727345 No abstract available.

10

Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond.

Mills SA, Gelbard MK. Mills SA, et al. World J Urol. 2020 Feb;38(2):269-277. doi: 10.1007/s00345-019-02818-3. Epub 2019 Jun 5. World J Urol. 2020. PMID: 31168744 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters